Compare Charles River Laboratories Intl. Inc (CRL) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Xcel Energy Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $232.53 (market cap $11.14B), while Xcel Energy Inc trades at $80.98 (market cap $50.05B). The key difference: Xcel Energy Inc is far larger — about 4.5× Charles River Laboratories Intl. Inc's market cap, and Xcel Energy Inc pays a 2.96% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | XEL | |
|---|---|---|
Market Cap | $11.14B | $50.05B |
Sector | Health | Utilities |
52-Week High | $233.60 | $83.91 |
52-Week Low | $145.57 | $68.33 |
Enterprise Value | $14.00B | $87.49B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
XEL trades at $80.48, up 0.52% today, with a bullish technical signal and strong analyst consensus. Recent earnings show a Q1 2026 beat, while Q3 and Q4 2025 missed expectations. The company's $60 billion capital plan through 2030 aims to capitalize on rising electricity demand, supporting projected EPS growth. Cash flow trends show improving net cash flow, reaching $637 million in 2026. The stock is near its 52-week high, with a consensus price target of $91.88 implying potential upside.
Outlook is positive due to robust capital investment and sector tailwinds, but regulatory pushback and high valuation pose risks. Analyst sentiment is predominantly bullish, with 63% buy ratings. Investors should weigh growth prospects against execution risks and current premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
